Coronary heart failure with diminished ejection fraction

Plain Language Abstract

Actual-world information are wanted to characterize affected person populations with coronary heart failure with diminished ejection fraction (HFrEF) that might profit from novel therapies. Utilizing the Vanderbilt College Medical Middle digital well being information, we recognized a scientific cohort based mostly on a validated HFrEF algorithm, in addition to a second cohort chosen to reflect enrollment necessities of the GALACTIC-HF scientific trial based mostly on hospitalizations, medicines, laboratory and different scientific values. Roughly 40% of RW HFrEF sufferers met standards for the GALACTIC-HF trial. Whereas findings of ongoing scientific trials could also be instantly generalizable to this sizable proportion of sufferers, whether or not nearly all of sufferers with decrease prevalence of comorbidities and charge of HF hospitalization may gain advantage from rising HF remedies must be thought-about in future trials.


Coronary heart failure with diminished ejection fraction (HFrEF) impacts a minimum of 3 million Individuals1,2 and, regardless of latest therapeutic advances, stays a scientific problem, with annual mortality above 25%. Thus far, there aren’t any protected medical therapies that instantly deal with the basic pathology of impaired cardiac contractility on the degree of the cardiac sarcomere.3 The general public well being burden of HFrEF has made it a excessive precedence for therapeutic improvement, and lots of new therapeutics are actually being evaluated in ongoing scientific trials.4 Gauging the exterior validity of scientific trials may be difficult as a result of people enrolled into research could also be extremely chosen.5 Finally, the potential impression of any novel therapeutic6 agent is decided by the variety of sufferers eligible to obtain it and the magnitude of the profit offered by the remedy. Thus, it’s critically vital to know the extent to which members in trials for HFrEF replicate the sufferers in scientific take care of whom the drug is meant, and an outline of affected person demographics, scientific traits and outcomes utilizing real-world information of sufferers doubtlessly eligible for focused interventions and new therapeutics is required to supply impactful real-world proof.

Given identified variations between real-world and scientific trial populations, we sought to characterize affected person demographics, scientific traits, and outcomes utilizing RW information for sufferers with HFrEF, together with these much like topics enrolled in an ongoing HFrEF scientific trial. Subsequently, we created two real-world cohorts of HFrEF sufferers utilizing a de-identified analysis database, the Artificial By-product (SD), derived from the digital well being file (EHR) of Vanderbilt College Medical Middle (VUMC). The primary cohort was based mostly solely on a scientific definition of HFrEF and the second cohort was based mostly on the inclusion and exclusion standards used within the phase-3 scientific trial (International Strategy to Decreasing Opposed Cardiac outcomes By Enhancing Contractility in Coronary heart Failure, GALACTIC-HF; NCT02929329) for remedy of HFrEF. GALACTIC-HF is a randomized, placebo-controlled, double-blind, parallel group, multicenter, cardiovascular (CV) outcomes research of omecamtiv mecarbil (OM), a first-in-class cardiac myosin activator, in topics with HFrEF.7

Supplies and Strategies


This research utilized info extracted from the VUMC SD database, a analysis instrument developed to allow research with de-identified scientific information. The SD is a de-identified copy of the VUMC EHR, and content material has been remodeled by deletion or permutation of all identifiers contained inside every file. The SD incorporates almost 3 million whole information (with no outlined exclusions) with extremely detailed longitudinal scientific information for roughly a million topics and a median of 27 distinct codes per file. The database incorporates information from a number of sources and consists of diagnostic and process codes (ICD and CPT), fundamental demographics (age, gender, race), textual content from scientific care together with discharge summaries, nursing notes, progress notes, historical past and bodily, drawback lists and multi-disciplinary assessments, laboratory values, electrocardiogram (ECG) diagnoses, procedural experiences (eg, echocardiography), scientific textual content and electronically derived hint values, and inpatient treatment orders. All information within the SD are up to date bimonthly to append new information to scientific information of current sufferers and add sufferers new to VUMC.

This research complies with the Declaration of Helsinki and was permitted by the Vanderbilt College Medical Middle Institutional Overview Board. As no HIPAA identifiers can be found within the Artificial By-product database, this research meets standards for non-human topics analysis.

VUMC HF Cohort

The Digital Medical Data and Genomics (eMERGE) Community phenotype of HF with differentiation for preserved and diminished ejection fraction was beforehand developed utilizing EHR information from the Mayo Clinic and validated in further Mayo Clinic populations in addition to inside the Group Well being Cooperative.8 Extra particulars can be found on-line: All information parts of the eMERGE HF algorithm have been beforehand extracted from the VUMC SD database. The ICD9 code 428.X, the structured drawback record, and the unstructured drawback record are the first sources for figuring out classification of HF within the SD in line with the eMERGE algorithm. To accommodate the discontinuation of ICD9 codes, we mapped ICD9 codes to ICD10 codes utilizing the CMS Basic Equivalence Mappings in addition to scientific experience (ICD9:428 ≤ ICD10:I50) and included the mapped ICD10 code within the algorithm. The structured drawback record makes use of a managed vocabulary that maps to SNOMED CT, whereas the unstructured drawback record is free textual content that makes use of ConText, the Pure Language Processing bundle, to confirm mentions of HF. Dedication of preserved or diminished ejection fraction relies on measurements taken from transthoracic echocardiogram (TTE) experiences when obtainable. Extra particulars can be found concerning the pseudocode.

The tailored algorithm was validated towards a set of gold customary HF topics at VUMC. The algorithm makes use of the date of the qualifying HF characteristic (ICD code or Drawback Record point out) because the eMERGE definition index date (“HF index date”), so long as that date falls between an admit and discharge. Moreover, for this research, a minimum of one TTE report was required to be obtainable within the particular person file. Thus, sufferers within the SD who’ve been identified with HF in line with the eMERGE Community definition and who’ve a TTE report made up the preliminary inhabitants of doubtless eligible topics for each cohorts on this research.

Cohort Definitions

Beginning with the possibly eligible inhabitants of HF sufferers within the SD who met the eMERGE Community definition for HF and who had an obtainable LVEF measurement from clinically indicated TTE, further inclusion standards for every cohort have been utilized to outline the 2 cohorts for this research. For the Medical Cohort, topics have been required to 1) be male or feminine ≥18 years previous and a couple of) have an LVEF ≤40%, utilizing measurement closest to check index date (see the “Examine Dates” part) with desire for measurements previous to index date. For the GALACTIC-HF-like Cohort, topics have been moreover required to be 1) be age 18–85 years on HF index date, 2) be lively within the SD for a minimum of 12 months after the HF index date, 3) have an LVEF ≤35%, per affected person’s most up-to-date TTE inside the 365-day interval previous to the HF index date or as much as 1-month after index (if no different TTE have been obtainable previous to index), 4) have B-type natriuretic peptide (BNP) degree ≥125 pg/mL at most up-to-date evaluation inside the three hundred and sixty five days interval previous to the HF index date, 5) have a minimum of one written customary of care (SoC) prescription or prescription allotted for an HFrEF treatment from VUMC Pharmacy or point out on SD Treatment Record of normal of care HF therapies. Customary of care HR therapies included beta blockers, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), angiotensin receptor blocker-neprilysin inhibitor (ARNi) and mineralocorticoid receptor antagonists, and 6) have been hospitalized for a major cause of HF or have an emergency division (ED) admission for a major cause of HF inside 1 12 months previous to the research index date. Topics have been excluded from the GALACTIC-HF-like Cohort in the event that they met any of the next: 1) historical past of malignancy outlined as any ICD code for a malignancy within the SD earlier than the index date; 2) extreme uncorrected valvular coronary heart illness, or clinically important congenital coronary heart illness; 3) estimated glomerular filtration charge (eGFR) <20 mL/min/1.73m2 per affected person’s most up-to-date medical file, inside 12 months prior to check index date; 4) receiving hemodialysis inside 12 months prior to check index date; 5) if obtainable, hepatic impairment outlined by a complete bilirubin (TBL) ≥2 occasions the higher restrict of regular (ULN), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 occasions ULN inside the 12 months previous to the research index date.

Examine Dates

The research index date was decided for the Medical Cohort because the eMERGE definition index date (first HF characteristic within the 12-month qualifying window for the eMERGE definition). This encounter may have been both an inpatient or an outpatient encounter. The index date for the GALACTIC-HF-like Cohort was chosen so as to most carefully mimic the entry procedures for the GALACTIC-HF trial inside the current eMERGE-defined HF cohort and thus was assigned individually for 2 non-overlapping teams outlined by the kind of encounter of their first eMERGE definition characteristic (hospitalization or outpatient encounter). For sufferers with a hospitalization as the primary eMERGE definition characteristic, the research index date was outlined because the eMERGE definition index date. For sufferers with an outpatient encounter as the primary eMERGE definition characteristic, information have been examined beginning on the eMERGE index date shifting ahead in time to an HF hospitalization after which a subsequent HF encounter (inpatient or outpatient) occurring ≤three hundred and sixty five days after the hospitalization. This encounter date was decided to be the research index date. Examine index dates have been restricted to prevalence inside the interval of 2006–2019. The baseline interval was outlined for each cohorts because the 1-year interval previous to the index date as outlined above.

Examine Knowledge

Covariates abstracted for eligible sufferers have been descriptive affected person traits together with demographics, comorbidities, laboratory measures (BNP, eGFR), very important indicators (blood stress and coronary heart charge), and drugs use. For every topic, all very important signal measures taken through the baseline have been averaged collectively and this abstract worth was then averaged with the abstract worth from all different topics. A biologic plausibility cut-off was utilized to the very important indicators information with values >200 beats per minute for coronary heart charge being set to lacking and values >150 mmHg for diastolic blood stress being set to lacking.

Comorbidities have been obtained through the baseline interval from the SD utilizing validated algorithms of diagnostic and process codes developed to establish these situations utilizing EHR information (Supplementary Materials). Presence of cardiac gadgets was ascertained through the baseline interval in addition to in any current information previous to the baseline interval so as to extra precisely depend sufferers who had ever acquired a tool. Laboratory measures have been additionally obtained through the baseline interval. Medicines have been obtained from the SD as Sure/No to ever use. Distributed prescription information from a VUMC Pharmacy are contained instantly inside a person’s SD file. Extra sources inside the SD routinely used for identification of treatment use embody scientific paperwork, outpatient and inpatient orders, medicines administered throughout inpatient care, drawback lists, medical histories, and discharge notes; inside these SD sources, information on treatment use are contained as written prescriptions, record of inpatient medicines administered, treatment record entries, or affected person self-reported treatment (recognized from notes and browse by NLP program “MedEx”).9

Outcomes assessed throughout follow-up included HF hospitalization, and dying when obtainable. Comply with-up for every cohort for HF hospitalization or dying started on the research index date and continued till the affected person’s final SD encounter or date of dying, whichever occurred first. Comply with-up within the SD was obtainable via April 30, 2020. Full ascertainment of dying, nevertheless, was obtainable solely via February 1, 2017, so for analyses of dying as the end result, follow-up was truncated for all members on that date.

Statistical Strategies

All analyses have been descriptive in nature. Categorical variables have been described by way of pattern sizes (N) and percentages (%). Steady variables have been described by way of imply, median, customary deviation, minimal, and most. Charges of HF hospitalization have been calculated as incidence charges from 3 days submit HF index date to final SD encounter or dying and offered as variety of occasions per 1000 person-years. Three days was chosen after contemplating a spread of censoring home windows (ie, days after index date earlier than occasions have been captured) so as to consider the stability of avoiding the index occasion within the counts whereas capturing most occasions throughout follow-up. Incidence charges included solely the primary HF hospitalization captured throughout follow-up.


The eMERGE Community definition of HF was utilized to the >3 million information within the SD and 38,668 sufferers met the definition for HF (Determine 1). Proscribing to these with a transthoracic echocardiogram-derived ejection fraction resulted in 27,586 topics, which was additional diminished to 5488 when topics with a preserved ejection fraction and people with no ejection fraction earlier than their index date have been excluded. Proscribing to these with an index date from 1/1/2006 to 12/31/2019 in addition to the necessities of the Medical Cohort resulted in 3954 topics. These sufferers have been then evaluated towards the standards for the GALACTIC-HF-like Cohort and grouped accordingly, with 3954 sufferers within the Medical Cohort and the subgroup of these (N=1541) assembly standards for inclusion within the GALACTIC-HF-like Cohort.

Determine 1 Cohort circulate diagram.

Descriptive traits of the 2 cohorts are proven in Desk 1. The Medical Cohort was older than the GALACTIC-HF-like Cohort at index (median 64.6 versus 60.5 years). Each cohorts have been two-thirds male. The Medical Cohort was 80.7% White in contrast with 77.4% within the GALACTIC-HF-like Cohort. On account of the research design which required sufferers within the GALACTIC-HF-like Cohort to be lively within the SD for a minimum of 12 months after the HF index date, the minimal follow-up for this cohort is 1 12 months. Within the Medical Cohort, there was no such restriction and thus the minimal follow-up may very well be as quick as a single day. This resulted in an extended median follow-up time for the GALACTIC-HF-like Cohort (median 4.2 years, vary 1–13.6) versus the Medical Cohort (median 2.9 years, vary 0–13.8).

Desk 1 Demographic and Medical Traits of Medical and GALACTIC-HF-Like Cohortsa

Medical traits of the 2 cohorts, together with very important indicators and laboratory measurements, are summarized in Desk 1. Coronary heart charge was increased on common within the GALACTIC-HF-like Cohort in contrast with the Medical Cohort (median 82 vs 77 bpm). Each BMI and diastolic blood stress was comparable between the 2 teams, whereas systolic blood stress was barely decrease within the GALACTIC-HF-like Cohort (115 vs 121 mmHg). Imply BNP values have been increased within the GALACTIC-HF-like Cohort than within the Medical Cohort (820.8 vs 506.0 pg/mL), however eGFR values have been comparable in each cohorts. The median LVEF within the Medical Cohort was 30% versus 22.5% within the GALACTIC-HF-like Cohort, a distinction a minimum of partially because of the research design, which utilized completely different cut-offs for inclusion in every cohort (LVEF ≤40% for Medical and ≤35% for GALACTIC-HF-like).

Desk 2 gives a abstract of comorbidity prevalence and use of cardiac gadgets within the cohorts through the baseline interval. Typically, comorbidities have been considerably extra widespread within the GALACTIC-HF-like Cohort than within the Medical Cohort though this must be interpreted with warning on condition that the GALACTIC-HF-like Cohort had a minimal of 1 12 months and total longer imply follow-up than the Medical Cohort by design. Greater than half of the topics had coronary artery illness (55% of the scientific and 64% of the GALACTIC-HF-like Cohort), and hypercholesterolemia was widespread (69% within the Medical and 74% within the GALACTIC-HF-like Cohorts). Continual kidney illness (31 vs 21%), atrial fibrillation (32 vs 29%), and cardiac resynchronization or implantable cardioverter defibrillator (26 vs 23%) have been increased within the GALACTIC-HF-like Cohort.

Desk 2 Proportion of People with Choose Comorbidities and Cardiac Gadgets at Baseline in Medical and GALACTIC-HF-Like Cohorts

Desk 3 shows the prevalence of use of medicines for HFrEF and chosen different continual situations through the one-year baseline interval by cohort. With respect to generally used HFrEF remedies, use of an ACE inhibitor was excessive in each teams however extra widespread within the GALACTIC-HF-like Cohort (71% and 82%, respectively), and beta-blockers or loop diuretics have been utilized by over 90% of the people in each cohorts. Mineralocorticoid receptor antagonists (55% and 77%, respectively) and ARBs (39% and 46%, respectively) have been used considerably much less steadily, however a sample of upper use within the GALACTIC-HF-like Cohort in comparison with the Medical Cohort was obvious additionally for these medicines. Over 75% of the sufferers in each teams have been prescribed statins.

Desk 3 Prevalence of Focused Medicines Publish-Ascertainment in Medical and GALACTIC-HF-Like Cohorts

Occasion charges are displayed in Determine 2 for HF hospitalizations and deaths per 1000 person-years. Each coronary heart failure hospitalization charges and dying charges have been increased within the GALACTIC-HF-like Cohort in contrast with the Medical Cohort. With a 3-day post-index censoring window, HF hospitalization charges have been 261 (95% CI 224, 297) per 1000 person-years within the Medical cohort versus 523 (484, 562) within the GALACTIC-HF-like Cohort, throughout median follow-up of two.9 and 4.2 years, respectively. Loss of life charges have been 260 (207, 313) and 277 (94, 460) per 1000 person-years within the Medical Cohort and GALACTIC-HF-like Cohort, respectively.

Determine 2 Coronary heart failure hospitalizations and deaths per 1000 person-years in Medical and GALACTIC-HF-like Cohorts. Footnote: Bars present occasions per 1000 person-years; whiskers present 95% confidence intervals. There have been a complete of 2117 HF hospitalizations within the Medical Cohort and 1180 within the GALACTIC-HF-like Cohort. There have been a complete of 1019 deaths within the Medical Cohort and 379 within the GALACTIC-HF-like Cohort.


A transparent understanding of affected person demographics, scientific traits, and outcomes amongst HFrEF sufferers from a real-world information useful resource is crucial to outline affected person populations that will profit from novel HFrEF therapies. On this research, performed inside the VUMC EHR database, almost 4000 sufferers have been recognized who met a validated scientific definition of HFrEF8 between 2006 and 2019. A subset of roughly 40% of those sufferers met the extra stringent inclusion standards of the GALACTIC-HF trial.6 This discovering means that outcomes of present scientific trials for brand spanking new therapeutics could also be instantly generalizable to a large proportion of real-world HFrEF sufferers in scientific observe. Nonetheless, whether or not the remaining majority of HFrEF sufferers with decrease prevalence of comorbidities and decrease charge of HF hospitalization may gain advantage from rising HF remedies must be thought-about in future trials.

Though this evaluation was performed in a single quaternary care hospital with a high-volume HF and transplantation program geographically situated in a area with a excessive burden of HF, the findings, together with demographic and scientific traits, are largely in settlement with printed baseline information from GALACTIC-HF and different scientific trial6,10,11 and group populations,12 reminiscent of the worldwide PARADIGM-HF trial, the VICTORIA trial, and the latest PCORnet publication and are seemingly related to the broader HF inhabitants.10,13 Of be aware is the final comparability of baseline traits between the GALACTIC-HF-like Cohort in our research and the GALACTIC-HF trial members,6 together with imply age (61 vs 65 years, respectively), race (77 vs 78% white), prevalence of coronary artery illness (64 vs 62%), and median eGFR (65 vs 59 mL/min/1.73m2). Prevalence of sure comorbidities reminiscent of atrial fibrillation/flutter and diabetes was decrease in our GALACTIC-HF-like Cohort than within the GALACTIC-HF trial, and there was a better proportion of girls in our cohort (32 vs 21%).

Though particular observe patterns and use of evidence-based therapies are identified to fluctuate by geographic area or illness severity and throughout scientific settings, goal-directed medical remedy, together with ACE inhibitors, beta blockers, and mineralocorticoid receptor antagonists, has been the cornerstone of HFrEF remedy for many years. This method follows constant proof from trials displaying a diminished threat of dying and/or hospitalization as a consequence of HF related to use of those medicines.14–19 As anticipated, the noticed patterns of treatment use within the two real-world cohorts in our research are in step with this method to HFrEF remedy, displaying excessive prevalence of use of ACE inhibitors and beta-blockers in each cohorts, in keeping with proof that, when used along with ACE inhibitors, beta-blockers are related to incremental decreases within the threat of dying14,20–23 amongst HFrEF sufferers. Use of mineralocorticoid receptor antagonists was considerably increased within the GALACTIC-HF-like Cohort, which can be an indicator of its predominant use in sicker HFrEF sufferers who’re taking different medicine identified to enhance outcomes.22 In our research cohorts, with enrollment from 2006–2019, the low prevalence of use of SGLT2 inhibitors (<3%) is probably going a mirrored image of their latest approval for discount of cardiovascular dying and HF hospitalization amongst HFrEF24–27 sufferers with and with out Sort 2 diabetes. Nonetheless, through the overwhelming majority of the research interval, there have been no novel brokers launched to escalate take care of HFrEF sufferers experiencing clinically-relevant outcomes, underscoring the necessity for novel therapeutics for HFrEF and for future work to find out uptake of latest therapies and potential interventions which may be wanted to extend utilization of therapies for which efficacy is demonstrated.

Medical trials typically enroll increased threat affected person populations the place energy is best to detect helpful results of novel therapies. Certainly, topics included within the GALACTIC-HF, and different latest trials, typically have high-risk options together with present/latest hospitalization, elevated BNP ranges, and severely depressed LV operate. The truth that 40% of our HFrEF sufferers met these inclusion standards reinforces the excessive burden of extreme HF amongst sufferers in scientific care. Furthermore, the excessive charge of HF hospitalization in each the Medical Cohort and GALACTIC-HF-like Cohort in our research, regardless of the usage of customary medical remedy for HF, point out that these sufferers have residual threat and contribute to the excessive healthcare burden of HF.

Our evaluation has limitations that must be acknowledged. Whereas we consider our findings are related extra broadly, this was a single-center research and there could also be features of our affected person inhabitants that scale back the generalizability of our outcomes. For instance, people in our research have been predominantly white, and outcomes must be replicated in populations with completely different racial composition. Moreover, referral and observe patterns could differ throughout establishments, which may have an effect on the generalizability of our findings. It is usually attainable that some information parts have been under-ascertained as a consequence of care encounters at different establishments. Nonetheless, the substantial follow-up time in our research ought to considerably attenuate under-ascertainment by assuring that topics had enough alternatives for comorbidity documentation. Moreover, though misclassification associated to errors in EHR documentation is feasible, we addressed this weak spot via the usage of validated phenotype algorithms. As complete mortality linkages to the SD have been present solely via 2017, the evaluation of dying charges was restricted to follow-up via 2017 solely. Lastly, whereas mirrored as carefully as attainable in our dataset, we have been unable to completely match GALACTIC-HF trial inclusion and exclusion standards.


Our research highlights further features of HFrEF sufferers in the true world. Though a considerable variety of sufferers have been much like scientific trial populations, and accounted for a bigger variety of antagonistic outcomes, over half of the HFrEF sufferers didn’t meet GALACTIC-HF trial inclusion standards6 though they nonetheless skilled excessive charges of HF hospitalizations and deaths. It’s encouraging that outcomes of ongoing trials will seemingly be related to a lot of high-risk HFrEF sufferers; nevertheless, the extent to which they are going to be generalizable to all HFrEF sufferers is much less clear and will must be addressed in future trials that enroll sufferers extra broadly throughout the spectrum of HFrEF severity.


ARB, angiotensin receptor blockers; ACEi, angiotensin-converting enzyme inhibitors; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ARNi, angiotensin receptor blocker-neprilysin inhibitor; BNP, B-type natriuretic peptide; CV, cardiovascular; ECG, electrocardiogram; ED, emergency division; eGFR, estimated glomerular filtration charge; EHR, digital well being file; eMERGE, Digital Medical Data and Genomics; GALACTIC-HF, International Strategy to Decreasing Opposed Cardiac outcomes By Enhancing Contractility in Coronary heart Failure; HFrEF, coronary heart failure with diminished ejection fraction; LVEF, left ventricular ejection fraction; OM, omecamtiv mecarbil; RW, actual world; SD, artificial spinoff; SoC, customary of care; TBL, whole bilirubin; TTE, transthoracic echocardiogram; VUMC, Vanderbilt College Medical Middle; ULN, higher restrict of regular.

Knowledge Sharing Assertion

Vanderbilt College Medical Middle is firmly dedicated to sharing information with the scientific group in order that the info generated from this research may be absolutely utilized for analysis. VUMC additionally has an obligation to guard the privateness of research members and the confidentiality of research information, since this venture is an ancillary research of the Vanderbilt Artificial By-product, which has pointers in place that allow scientific investigators to use to be used of those information. The Vanderbilt BioVU public availability is described on the VICTR web site: Aggregated statistics shall be offered to the broad scientific group through the journal’s website online or to a person investigator/crew upon request.

Writer Contributions

All authors made a big contribution to the work reported, whether or not that’s within the conception, research design, execution, acquisition of knowledge, evaluation and interpretation, or in all these areas; took half in drafting, revising or critically reviewing the article; gave ultimate approval of the model to be printed; have agreed on the journal to which the article has been submitted; and comply with be accountable for all features of the work.


This work was supported by a analysis grant to EpidStrategies from Amgen, Inc., Thousand Oaks, CA, USA. The venture was additionally supported by the Nationwide Middle for Analysis Sources, Grant UL1 RR024975-01, and is now on the Nationwide Middle for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content material is solely the duty of the authors and doesn’t essentially signify the official views of the NIH.


Paul Dluzniewski, Ricardo Dent, and John Umeijiego are workers and stockholders of Amgen, Inc. Sarah S Cohen is an worker of EpidStrategies, A D ivision of ToxStrategies, Inc., who acquired analysis funds from Amgen, Inc. All different authors don’t have any monetary or non-financial pursuits to declare.


1. Virani SS, Alonso A, Benjamin EJ, et al. Coronary heart illness and stroke statistics-2020 replace: a report from the American Coronary heart Affiliation. Circulation. 2020;141(9):e139–e596. doi:10.1161/CIR.0000000000000757

2. Shah KS, Xu H, Matsouaka RA, et al. Coronary heart failure with preserved, borderline, and diminished ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476–2486. doi:10.1016/j.jacc.2017.08.074

3. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a possible therapeutic method for systolic coronary heart failure. Science. 2011;331(6023):1439–1443. doi:10.1126/science.1200113

4. Kish T. New coronary heart failure medicines goal to fill important gaps in remedy. P T. 2017;42(12):764–766.

5. Rothwell PM. Exterior validity of randomised managed trials: “to whom do the outcomes of this trial apply?”. Lancet. 2005;365(9453):82–93. doi:10.1016/S0140-6736(04)17670-8

6. Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in continual coronary heart failure with diminished ejection fraction: GALACTIC-HF baseline traits and comparability with up to date scientific trials. Eur J Coronary heart Fail. 2020;22(11):2160–2171.

7. Kaplinsky E, Mallarkey G. Cardiac myosin activators for coronary heart failure remedy: give attention to omecamtiv mecarbil. Medication Context. 2018;7:212518. doi:10.7573/dic.212518

8. Bielinski SJ, Pathak J, Carrell DS, et al. A strong e-Epidemiology Software in phenotyping coronary heart failure with differentiation for preserved and diminished ejection fraction: the Digital Medical Data and Genomics (eMERGE) community. J Cardiovasc Transl Res. 2015;8(8):475–483. doi:10.1007/s12265-015-9644-2

9. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC MedEx: a medicine info extraction system for scientific narratives. J Am Med Inform Assoc. 2010;17(1):19–24.

10. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in coronary heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077

11. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in sufferers with coronary heart failure and diminished ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303

12. Mentz RJ, Xu H, O’Brien EC, et al. PROVIDE-HF major outcomes: patient-reported outcomes investigation following initiation of drug remedy with Entresto (sacubitril/valsartan) in coronary heart failure. Am Coronary heart J. 2020;230:35–43. doi:10.1016/j.ahj.2020.09.012

13. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in sufferers with coronary heart failure and diminished ejection fraction. N Engl J Med. 2020;382(20):1883–1893. doi:10.1056/NEJMoa1915928

14. Packer M, Fowler MB, Roecker EB, et al. Impact of carvedilol on the morbidity of sufferers with extreme continual coronary heart failure: outcomes of the carvedilol potential randomized cumulative survival (COPERNICUS) research. Circulation. 2002;106(17):2194–2199. doi:10.1161/01.CIR.0000035653.72855.BF

15. CONSENSUS Trial Examine Group. Results of enalapril on mortality in extreme congestive coronary heart failure. Outcomes of the Cooperative North Scandinavian Enalapril Survival Examine (CONSENSUS). N Engl J Med. 1987;316(23):1429–1435. doi:10.1056/NEJM198706043162301

16. Hjalmarson A, Goldstein S, Fagerberg B, et al. Results of controlled-release metoprolol on whole mortality, hospitalizations, and well-being in sufferers with coronary heart failure: the Metoprolol CR/XL randomized intervention trial in congestive coronary heart failure (MERIT-HF). MERIT-HF Examine Group. JAMA. 2000;283(10):1295–1302. doi:10.1001/jama.283.10.1295

17. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Impact of enalapril on survival in sufferers with diminished left ventricular ejection fractions and congestive coronary heart failure. N Engl J Med. 1991;325(5):293–302.

18. Rossello X, Ariti C, Pocock SJ, et al. Affect of mineralocorticoid receptor antagonists on the chance of sudden cardiac dying in sufferers with coronary heart failure and left-ventricular systolic dysfunction: a person patient-level meta-analysis of three randomized-controlled trials. Clin Res Cardiol. 2019;108(5):477–486. doi:10.1007/s00392-018-1378-0

19. Wikstrand J, Wedel H, Castagno D, McMurray JJ. The big-scale placebo-controlled beta-blocker research in systolic coronary heart failure revisited: outcomes from CIBIS-II, COPERNICUS and SENIORS-SHF in contrast with stratified subsets from MERIT-HF. J Intern Med. 2014;275(2):134–143. doi:10.1111/joim.12141

20. MERIT-HF. Impact of metoprolol CR/XL in continual coronary heart failure: metoprolol CR/XL randomised intervention trial in congestive coronary heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007. doi:10.1016/S0140-6736(99)04440-2

21. CIBIS-II. The cardiac insufficiency Bisoprolol research II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. doi:10.1016/S0140-6736(98)11181-9

22. Pitt B, Zannad F, Remme WJ, et al. The impact of spironolactone on morbidity and mortality in sufferers with extreme coronary heart failure. Randomized Aldactone Analysis Examine Investigators. N Engl J Med. 1999;341(10):709–717. doi:10.1056/NEJM199909023411001

23. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in sufferers with systolic coronary heart failure and delicate signs. N Engl J Med. 2011;364(1):11–21. doi:10.1056/NEJMoa1009492

24. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal occasions in sort 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925

25. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in sort 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744

26. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in sort 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389

27. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in sort 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720

Related Articles

Back to top button